---
title: "management of Stage IV metastatic disease of NSCLC"
slug: "management-of-stage-iv-metastatic-disease-of-nsclc"
date: "2023-11-09"
enableToc: false
tags:
  - building
---

> [!info]
>
> ðŸŒ± ä¾†è‡ª: [[management of Stage IV metastatic disease]]

# management of Stage IV metastatic disease of NSCLC

- 6-mo BSC, 10-mo plat doublet, 12-mo plat doublet + Bev (NEJM 2006;355:2542), 3-y EGFR Mt EGFR TKI, 5-y+ ALK Mt ALK TKI 5y OS: 20% if PD-L1+, 30% if PD-L1 â‰¥50% to checkpoint inhibitor (JCO 2019;37:2518), â†‘ OS w/ early palliative care (NEJM 2010;363:733)
- Initial tx: If sensitizing EGFR/ALK, see Targeted therapy; If driver neg, pembrolizumab, atezolizumab, cemiplimab if PD-L1â‰¥50% (RR âˆ¼45%) (NEJM 2016;375:1823). If PD-L1 <50%, 4-6 cycles of plat doublet+checkpoint inhibitor (RR âˆ¼50%) (NEJM 2018;378:2078; NEJM 2018;379:2040). AdenoCAs: CIS or carbo/peme Â± Bev (if eligible: No-SQCLC, no hemoptysis) vs. SQCLC: Carbo/paclitaxel, nab-paclitaxel
- Other initial: Ipi/nivo in TMB â‰¥10 mt/mb (NEJM 2018;378:2093), atezo+carbo/taxol+ Bev in non-SQCLC, EGFR/ALK post TKI (NEJM 2018;378:2288), ipi/Nivo w/ plat doublet x2cy (Lancet Onc 2021;22:198)
- Maintenance tx: For CR/PR/SD after 4-6 cycles of plat doublet. D/c plat. Continue peme â†‘ OS (PARAMOUNT, JCO 2013;31:2895), peme + Bev â†‘ PFS (AVAPERL, JCO 2013;31:3004), GEM â†‘ PFS (JCO 2012;30:3516)
- Subsequent therapies: Nab-paclitaxel, docetaxel, peme, GEM, vinorelbine, checkpoint inhibitors if not prior: Nivo, pembrolizumab, atezolizumab, ramucirumab + docetaxel (Lancet 2014;384:665)
- Limited met sites: (Oligomets): Consider surgery, RT, ablation
- RT to symptomatic sites: Lung, brain (SRS preferred over WBRT), bone lesions, SVC syn
- Bone Mets: Denosumab or ZA reduces SRE; symptomatic: Palliative RT
- Brain Mets: Multidisciplinary involvement of neuro-oncology/neurology, rad onc/neurosurgery; symptomatic: Start dexamethasone
- Leptomeningeal dz: Consider VP shunt if symptomatic w/ ataxia, encephalopathy, urinary incontinence; WBRT role limited (JTO 2012;7:382). If EGFR Mt (double dose) osimertinib 180 mg (JCO 2020;38:538).
- Symptomatic pleural effusion: PleurX w/ talc pleurodesis (NEJM 2018;378:1313), thoracic surgery referral for VATS pleurodesis
